Can Bayer Show A "Small Lesion" Advantage For Its MRI Agent Gadovist?
This article was originally published in The Pink Sheet Daily
The gadolinium contrast agent for MRI imaging comes up for review by FDA's Peripheral and Central Nervous System Drugs Advisory Committee Jan. 21.
You may also be interested in...
Updated labeling for five such agents follows reports of nephrogenic systemic fibrosis after administration.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.